ArticleDigital health
Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of precision oncology research in pediatric poor prognosis cancer: patient, parent and healthcare provider perspectives.BMC cancer · 2026Article
- Ethical Challenges and Considerations in Decentralized Clinical Trials (DCTs): Insights from a Scoping Review.Therapeutic innovation & regulatory science · 2026Article
- Adaptation of Clinical Research Staff to Decentralized Clinical Trials and Impacts on the Patient-Centered Experience: Qualitative Interview Study.Journal of medical Internet research · 2025Article
- Sample-size determination for decentralized clinical trials.International journal of epidemiology · 2025Article
- Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials.Journal of the National Cancer Institute. Monographs · 2025Article
- Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: "It's About Time we Bring Trials to People".Therapeutic innovation & regulatory science · 2024Article
- Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers.ESMO open · 2024Review
- TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.Cancer medicine · 2024Article
- Narrative review of telemedicine applications in decentralized research.Journal of clinical and translational science · 2024Review
- Leveraging Virtual Technology to Conduct Clinical Trials in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2023Article
- Clinical trial reform in the post-COVID era.Therapeutic advances in medical oncology · 2023Review
- Methods and perceptions of success for patient recruitment in decentralized clinical studies.Journal of clinical and translational science · 2023Review
- Towards a conceptual framework for addressing state-level barriers to decentralized clinical trials in the U.S.Journal of clinical and translational science · 2023Article
- Exploring patient experiences with a telehealth approach for the PRO-ACTIVE trial intervention in head and neck cancer patients.BMC health services research · 2022Article
- Drug development process and COVID-19 pandemic: Flourishing era of outsourcing.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a result of the unprecedented challenges imposed by the COVID-19 pandemic on enrollment to cancer clinical trials, there has been an urgency to identify and incorporate new solutions to mitigate these difficulties. The concept of decentralized or hybrid clinical trials has rapidly gained currency, given that it aims to reduce patient burden, increase patient enrollment and retention, and preserve quality of life, while also increasing the efficiency of trial logistics. Therefore, the clinical trial environment is moving toward remote collection and assessment of data, transitioning from the classic site-centric model to one that is more patient-centric.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.